NASA Notice of Intent To Grant Exclusive License: Meridian Health Systems
[Federal Register Volume 76, Number 117 (Friday, June 17, 2011)] [Notices] [Page 35480] From the Federal Register Online via the Government Printing Office [www.gpo.gov] [FR Doc No: 2011-15025]
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
[Notice (11-052)]
Notice of Intent To Grant Partially Exclusive License
AGENCY: National Aeronautics and Space Administration.
ACTION: Notice of intent to grant partially exclusive license.
SUMMARY: This notice is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant a partially exclusive license in the United States to practice the inventions described and claimed in USPN 6,047,216, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC- 22724-1, USPN 6,226,553, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC-22724-2, USPN 6,223,086, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC- 22724-3, and USPN 6,496,736, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC-22724-5 to Meridian Health Systems, P.C., having its principal place of business in Los Angeles, California. The patent rights in these inventions have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective partially exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
DATES: The prospective partially exclusive license may be granted unless within fifteen (15) days from the date of this published notice, NASA receives written objections including evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Competing applications completed and received by NASA within fifteen (15) days of the date of this published notice will also be treated as objections to the grant of the contemplated partially exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
ADDRESSES: Objections relating to the prospective license may be submitted to Patent Counsel, Office of Chief Counsel, 2101 NASA Parkway, Houston, Texas 77058, Mail Code AL; Phone (281) 483-3021; Fax (281) 483-6936.
FOR FURTHER INFORMATION CONTACT: Theodore U. Ro, Intellectual Property Attorney, Office of Chief Counsel, 2101 NASA Parkway, Houston, Texas 77058, Mail Code AL; Phone (281) 244-7148; Fax (281) 483-6936. Information about other NASA inventions available for licensing can be found online at http://technology.nasa.gov/.
Dated: June 13, 2011. Richard W. Sherman, Deputy General Counsel. [FR Doc. 2011-15025 Filed 6-16-11; 8:45 am] BILLING CODE
